Synthego
US Patent Office Invalidates Two Agilent Technologies Patents Covering CRISPR Guide RNAs
Synthego, an Agilent competitor in the gene editing market, had initiated an inter partes review in January 2022 as part of a plan to ward off patent infringement allegations.
Synthego Preemptively Sues Agilent Technologies to Ward Off CRISPR Patent Infringement Allegations
Agilent allegedly tried to get Synthego to license patents related to CRISPR guide RNAs and threatened to escalate its response when Synthego did not do so.
CRISPR Researchers Engineer Guide RNAs to Enhance Cas13 Gene Knockdown
The modified guide RNAs increased CRISPR editing efficiencies two- to fivefold over the editing efficiency achieved with unmodified guides, the researchers said.